Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Hemostasis01:24

Disorders of Hemostasis

2.8K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.8K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

345
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
345
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

261
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
261
Liver Physiology01:30

Liver Physiology

4.4K
The liver, an essential organ in the human body, performs over 200 vital functions that can be broadly categorized into metabolic, hematological, endocrine regulation, and bile production.
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of  70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...
4.4K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.5K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.5K
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

15.7K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
15.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Novel Viscoelastic Tool Highlighting Severity-Dependent Platelet Dysfunction in Cirrhosis.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Managing Coagulation Abnormalities, Bleeding, and Thrombosis in Patients with Cirrhosis.

Journal of general internal medicine·2026
Same author

Discrepancies of results for post infusion levels of extended half-life factor VIII/IX concentrates - a cause of concern, awaiting for solution.

Clinical chemistry and laboratory medicine·2026
Same author

Measurement uncertainty of ISO 17511:2020 compliant and globally standardized PT/INR test results.

Research and practice in thrombosis and haemostasis·2026
Same author

Characterization of allogeneic platelet gel from adult donor blood and umbilical cord blood activated with locally prepared cryoprecipitate and thrombin: A pilot exercise.

Transfusion·2026
Same author

Measuring Direct Oral Anticoagulant Levels in Laboratory Practice: Impact of Different Storage Conditions of Blood Samples.

International journal of laboratory hematology·2025

Related Experiment Video

Updated: Apr 10, 2026

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
09:19

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

9.9K

Liver Disease and Hemostatic (Dys)function.

Armando Tripodi1

  • 1Department of Clinical Sciences and Community Health, Università degli Studi di Milano and IRCCS Cà Granda Ospedale Maggiore Foundation, Milano, Italy.

Seminars in Thrombosis and Hemostasis
|June 17, 2015
PubMed
Summary
This summary is machine-generated.

Cirrhosis does not always mean bleeding risk. Coagulation tests like prothrombin time (PT) and activated partial thromboplastin time (aPTT) may not predict bleeding in patients with liver disease. Rebalanced hemostasis in cirrhosis warrants new management strategies.

More Related Videos

Assessment of Plasma Coagulation on Liver Tissue in a Large Animal Model In Vivo
06:23

Assessment of Plasma Coagulation on Liver Tissue in a Large Animal Model In Vivo

Published on: August 4, 2018

9.3K
Human Liver Spheroids from Peripheral Blood for Liver Disease Studies
09:51

Human Liver Spheroids from Peripheral Blood for Liver Disease Studies

Published on: January 27, 2023

2.3K

Related Experiment Videos

Last Updated: Apr 10, 2026

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
09:19

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

9.9K
Assessment of Plasma Coagulation on Liver Tissue in a Large Animal Model In Vivo
06:23

Assessment of Plasma Coagulation on Liver Tissue in a Large Animal Model In Vivo

Published on: August 4, 2018

9.3K
Human Liver Spheroids from Peripheral Blood for Liver Disease Studies
09:51

Human Liver Spheroids from Peripheral Blood for Liver Disease Studies

Published on: January 27, 2023

2.3K

Area of Science:

  • Hepatology
  • Hematology
  • Coagulation Science

Background:

  • Cirrhosis impairs liver synthetic capacity, decreasing procoagulant factors, traditionally linked to bleeding.
  • Abnormal coagulation tests (prothrombin time [PT], activated partial thromboplastin time [aPTT]) and bleeding events are common in cirrhosis.
  • Historically, PT and aPTT guided interventions, but this approach is being re-evaluated.

Purpose of the Study:

  • To challenge the traditional view of cirrhosis as a purely hemorrhagic disorder.
  • To explore the concept of a rebalanced coagulation system in cirrhosis.
  • To reassess the predictive value of traditional coagulation tests for bleeding risk.

Main Methods:

  • Review of existing literature on coagulation and hemostasis in cirrhosis.
  • Analysis of studies investigating thrombin generation in cirrhotic plasma.
  • Examination of research on primary hemostasis, including von Willebrand factor and platelet function.

Main Results:

  • Cirrhotic plasma generates normal amounts of thrombin, indicating a balanced coagulation system.
  • Primary hemostasis is rebalanced in cirrhosis, despite thrombocytopenia.
  • Increased von Willebrand factor levels compensate for reduced platelet count and function.

Conclusions:

  • Cirrhosis may not be the epitome of acquired hemorrhagic coagulopathies.
  • Traditional coagulation tests (PT, aPTT) are unsuitable predictors of bleeding risk in cirrhosis.
  • New paradigms in understanding cirrhosis-related hemostasis have significant implications for patient management.